Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

The search for novel targets in chronic myeloid leukaemia (CML) is ongoing, to improve treatment efficacy in refractory disease and increase eligibility for tyrosine kinase inhibitor (TKI) discontinuation. Increased frequency of Tregs and effector Tregs was evident at diagnosis, together with increased expression of T‐cell exhaustion markers, including in regulatory T cells at diagnosis and in patients with refractory disease. Plasma analysis revealed significantly increased levels of cytokines including tumour necrosis factor (TNF)‐a and interleukin (IL)‐6 at diagnosis, in keeping with a pro‐inflammatory state prior to treatment. We hence demonstrate T‐cell exhaustion and a pro‐inflammatory state at diagnosis in CML, likely secondary to leukaemia‐associated antigenic overload associated with increased disease burden.

• Publication year

  2022

• Venue

  British Journal of Haematology

• Publication date

  2022-07-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bjh.18302PMID 35802024PMCID 9544983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

  2022cited by this paper
• The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

  2021cited by this paper
• Therapeutic targeting of the inflammasome in myeloid malignancies

  2021cited by this paper
• Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape

  2021cited by this paper
• Treg sensitivity to FasL and relative IL-2 deprivation drive Idiopathic Aplastic Anemia immune dysfunction.

  2020cited by this paper
• What are the considerations for tyrosine kinase inhibitor discontinuation in chronic-phase chronic myeloid leukemia?

  2020cited by this paper
• Inhibition of Immune Cell Subsets Is Differentially Affected By Dasatinib Dosage in Patients with Chronic Phase CML

  2020cited by this paper
• Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML

  2018cited by this paper
• CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

  2017cited by this paper
• Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

  2017cited by this paper
• Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study

  2017cited by this paper
• Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

  2016cited by this paper
• Tumor-necrosis factor is a master of T cell exhaustion

  2016cited by this paper
• TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

  2016cited by this paper
• Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.

  2015cited by this paper
• Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

  2015cited by this paper
• Enhanced suppressor function of TIM‐3+FoxP3+ regulatory T cells

  2014cited by this paper
• First‐line treatment of 102 chronic myeloid leukemia patients with imatinib: A long‐term single institution analysis

  2014cited by this paper
• Suboptimal Responses in Chronic Myeloid Leukemia

  2011cited by this paper
• IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development.

  2011cited by this paper
• Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

  2009cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.

  2000cited by this paper
• Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients.

  1995cited by this paper
• Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

  1987cited by this paper

• TIGIT Blockade Potentiates the Anti-Leukemic Activity of Exercise-Mobilized Donor Lymphocytes and Expanded γδ T-Cells

  2026cites this paper
• The Role of the Bone Marrow Microenvironment in Leukemic Stem Cell Resistance: Pathways of Persistence and Selection.

  2025cites this paper
• Autophagy crosstalk with the immune microenvironment in chronic myeloid leukemia and serves as a biomarker for diagnosis and progression

  2025cites this paper
• Progress of research on PD-1/PD-L1 in leukemia

  2023cites this paper
• The Bone Marrow Immune Microenvironment in CML: Treatment Responses, Treatment-Free Remission, and Therapeutic Vulnerabilities

  2023cites this paper
• Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia

  2023cites this paper
• Comprehensive analysis of the immune pattern of T cell subsets in chronic myeloid leukemia before and after TKI treatment

  2023cites this paper
• Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype

  2022cites this paper
• Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

  2022cites this paper
• Regulation of hematopoietic and leukemia stem cells by regulatory T cells

  2022cites this paper